Cangrelor
HealthData.Gov
Updated Oct 29, 2026
About this dataset
Kengreal (cangrelor) is an intravenous antiplatelet medication that works by inhibiting platelet aggregation to reduce the risk of blood clots during certain heart procedures. It's supplied as a 50 mg lyophilized powder for injection by Chiesi USA, Inc., and was approved by the FDA in 2015. This information was generated using AI and is provided for informational and research purposes only.
Data and resources (1)
- HTML
Cangrelor
Access the FDA dataset for Cangrelor — ANDA 213551 submitted by Mylan Institutional LLC
Modified Apr 29, 2026